

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6617492

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	CHARLES RIVER LABORATORIES, INC.	02/22/2021
RECEIVING PARTY DATA		
Name:	CENTIVAX, INC.	
Street Address:	201 GATEWAY BOULEVARD	
City:	SOUTH SAN FRANCISCO	
State/Country:	CALIFORNIA	
Postal Code:	94080	
PROPERTY NUMBERS Total: 4		
Property Type	Number	
Application Number:	63013485	
Application Number:	63014948	
Application Number:	63074087	
Application Number:	15931654	
CORRESPONDENCE DATA		
Fax Number:	(650)493-6811	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	6504939300	
Email:	cehui@wsgr.com	
Correspondent Name:	WILSON SONSINI GOODRICH & ROSATI	
Address Line 1:	650 PAGE MILL ROAD	
Address Line 4:	PALO ALTO, CALIFORNIA 94304	
ATTORNEY DOCKET NUMBER:	60333-711 -CENTIVAX	
NAME OF SUBMITTER:	CECILIA HUI	
SIGNATURE:	/Cecilia Hui/	
DATE SIGNED:	03/23/2021	
Total Attachments: 5		
source=60333-700 Executed Corporate Assignment#page1.tif		
source=60333-700 Executed Corporate Assignment#page2.tif		
source=60333-700 Executed Corporate Assignment#page3.tif		

source=60333-700 Executed Corporate Assignment#page4.tif

source=60333-700 Executed Corporate Assignment#page5.tif

CORPORATE TO CORPORATE PATENT ASSIGNMENT

Docket Number: 60333-700

Charles River Laboratories, Inc., a corporation incorporated under the laws of the State of Delaware, having a place of business at 251 Ballardvale Street, Wilmington, MA 01887, (the "Assignor"), desires to assign the entire right, title and interest in and to the Inventions and Assigned Patents (each, as defined below) to Centivax, Inc., a corporation incorporated under the laws of the State of Delaware, having a place of business at 201 Gateway Boulevard, South San Francisco, CA 94080, (the "Assignee"), desires to acquire the Assignors entire right, title and interest, all on the terms and conditions set forth in this Patent Assignment.

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Assignor to have been received in full from said Assignee:

1. Said Assignor has obtained the entire right, title and interest in and to certain new and useful inventions and improvements disclosed in the following patent(s) and patent application(s) referenced in the attached "Schedule A" which were filed in the United States Patent and Trademark Office (the "Listed Patent(s)").

2. As used herein: "Assigned Patents" means (a) the Listed Patent(s), (b) all Patents that share priority with or claim priority to or from the Listed Patent(s), including each and every Patent that is a divisional, substitution, continuation, continuation-in-part, non-provisional, or national phase application of any of the Listed Patent(s), (c) all Patents applied for on an invention disclosed within the Patents included in foregoing subclauses (a)-(b), (d) each and every Patent granting, issuing or reissuing from any of the foregoing under subclauses (a)-(c), (e) each and every reissue, reexamination, renewal or extension of any kind of any of the foregoing under subclauses (a)-(d), and (f) each and every Patent filed outside the United States and corresponding to any of the foregoing under subclauses (a)-(e). "Patents" means (i) patents, certifications of inventions, inventor's certificates and other forms of protection granted on any invention in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, including those filed under the Paris Convention for the Protection of Industrial Property, The Patent Cooperation Treaty or otherwise, and (ii) applications therefor (whether provisional, converted provisional, utility, design, plant, utility model, non-provisional or otherwise).

3. Said Assignor does hereby sell, assign, transfer and convey unto said Assignee the entire right, title and interest (a) in and to the Assigned Patents, including the right to claim priority to and from said Assigned Patents; (b) in and to the inventions disclosed in the Assigned Patents, and in and to all embodiments of the inventions (the "Inventions") and (c) in and to all claims for past, present and future infringement of the Assigned Patents, including all rights to sue for and to receive and recover for Assignee's own use all past, present, and future lost profits, royalties, and damages of whatever nature recoverable from an infringement of the Assigned Patents.

4. Said Assignor hereby covenants and agrees to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such cooperation by said Assignor shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for filing, prosecuting or maintaining any of the Assigned Patents; (c) for filing, prosecuting or maintaining applications for reissuance of any said Assigned Patents; (d) for interference or other priority proceedings involving said Assigned Patents or Inventions; and (e) for legal proceedings involving said Inventions or Assigned Patents, including without limitation reissues and reexaminations, IPRs, opposition and other post-grant proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that reasonable expenses incurred by said Assignor in providing such cooperation shall be paid for by said Assignee.

5. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, and assigns, and shall be binding upon said Assignor and its assigns.

6. Said Assignor hereby warrants, represents and covenants that Assignor has not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

7. Said Assignor hereby requests that any Assigned Patents issuing or granting in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued or granted in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors and assigns.

8. This instrument will be interpreted and construed in accordance with the laws of the State of Delaware, without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement.

CORPORATE TO CORPORATE PATENT ASSIGNMENT

Docket Number: 60213-700

IN WITNESS WHEREOF, said Inventor(s) have executed and delivered this instrument to said Assignee as of the dates written below:

AGREED TO BY ASSIGNOR:
Charles River Laboratories, Inc.

Date: 22 Feb 2021

Signature: 

Name: Matthew Danie

Title: CVP + General Counsel

RECEIVED AND AGREED TO BY ASSIGNEE:
Centivax, Inc.

Date: 6 Mar 2021

Signature: 

Name:

Title:

Jacob Glanville
CEO

Schedule A

WSGR Ref. No.	Title	Jurisdiction	Appl. No.	Filing Date	Patent Number
60333-701.101	EPITOPE FOCUSING BY VARIABLE EFFECTIVE ANTIGEN SURFACE CONCENTRATION	US	61/649,392	21-May-2012	
60333-701.102	EPITOPE FOCUSING BY VARIABLE EFFECTIVE ANTIGEN SURFACE CONCENTRATION	US	61/801,135	15-Mar-2013	
60333-701.301	EPITOPE FOCUSING BY VARIABLE EFFECTIVE ANTIGEN SURFACE CONCENTRATION	US	15/833,365	06-Dec-2017	10,196,427
60333-701.302	EPITOPE FOCUSING BY VARIABLE EFFECTIVE ANTIGEN SURFACE CONCENTRATION	US	16/231,294	21-Dec-2018	10,836,797
60333-701.401	EPITOPE FOCUSING BY VARIABLE EFFECTIVE ANTIGEN SURFACE CONCENTRATION	US	17/070,334	14-Oct-2020	
60333-701.601	EPITOPE FOCUSING BY VARIABLE EFFECTIVE ANTIGEN SURFACE CONCENTRATION	WO	PCT/US2013/042098	21-May-2013	
60333-701.831	EPITOPE FOCUSING BY VARIABLE EFFECTIVE ANTIGEN SURFACE CONCENTRATION	US	14/398,084	30-Oct-2014	9,884,893
60333-702.101	MAJOR HISTOCOMPATIBILITY COMPLEX (MHC) COMPOSITIONS AND METHODS OF USE THEREOF	US	62/609,589	22-Dec-2017	
60333-702.301	MAJOR HISTOCOMPATIBILITY COMPLEX (MHC) COMPOSITIONS AND METHODS OF USE THEREOF	US	16/899,512	11-Jun-2020	
60333-702.601	MAJOR HISTOCOMPATIBILITY COMPLEX (MHC) COMPOSITIONS AND METHODS OF USE THEREOF	WO	PCT/US2018/067380	21-Dec-2018	
60333-703.101	OPTIMIZED VACCINE COMPOSITIONS AND METHODS FOR MAKING THE SAME	US	62/808,760	21-Feb-2019	
60333-703.102	OPTIMIZED VACCINE COMPOSITIONS AND METHODS FOR MAKING THE SAME	US	62/817,902	13-Mar-2019	
60333-703.601	OPTIMIZED VACCINE COMPOSITIONS AND METHODS FOR MAKING THE SAME	WO	PCT/US2020/019367	21-Feb-2020	

60333-704.101	ANTIBODIES AND USES THEREOF	US	62/923,420	18-Oct-2019	
60333-704.201	ANTIBODIES AND USES THEREOF	US	17/072,258	16-Oct-2020	
60333-704.601	ANTIBODIES AND USES THEREOF	WO	PCT/US2020/056040	16-Oct-2020	
60333-705.101	POLYCLONAL POOLS OF POLYPEPTIDES	US	63/087,816	05-Oct-2020	
60333-706.101	ANTI-SARS-COV-2 ANTIBODIES AND USES THEREOF	US	62/993,630	23-Mar-2020	
60333-706.102	ANTI-SARS-COV-2 ANTIBODIES DERIVED FROM 2DD8	US	63/014,946	24-Apr-2020	
60333-706.103	ANTI-SARS-COV2 ANTIBODIES DERIVED FROM 2DD8	US	63/074,043	03-Sep-2020	
60333-706.201	ANTI-SARS-COV-2 ANTIBODIES DERIVED FROM 2DD8	US	15/931,642	14-May-2020	
60333-707.101	ANTI-SARS-COV2 ANTIBODIES DERIVED FROM 2GHW	US	63/014,058	22-Apr-2020	
60333-707.102	ANTI-SARS-COV2 ANTIBODIES DERIVED FROM 2GHW	US	63/014,556	23-Apr-2020	
60333-707.103	ANTI-SARS-COV2 ANTIBODIES DERIVED FROM 2GHW	US	63/074,050	03-Sep-2020	
60333-707.201	ANTI-SARS-COV2 ANTIBODIES DERIVED FROM 2GHW	US	15/931,643	14-May-2020	
60333-708.101	ANTI-SARS-COV2 ANTIBODIES DERIVED FROM 3BGF	US	63/014,942	24-Apr-2020	
60333-708.102	ANTI-SARS-COV2 ANTIBODIES DERIVED FROM 3BGF	US	63/074,056	03-Sep-2020	
60333-708.201	ANTI-SARS-COV-2 ANTIBODIES DERIVED FROM 3BGF	US	15/931,652	14-May-2020	
60333-709.101	ANTI-SARS-COV2 ANTIBODIES DERIVED FROM 6NB6	US	63/014,511	23-Apr-2020	
60333-709.102	ANTI-SARS-COV2 ANTIBODIES DERIVED FROM 6NB6	US	63/074,081	03-Sep-2020	
60333-709.201	ANTI-SARS-COV-2 ANTIBODIES DERIVED FROM 6NB6	US	15/931,648	14-May-2020	
60333-710.101	ANTI-SARS-COV2 ANTIBODIES DERIVED FROM CR3022	US	63/014,546	23-Apr-2020	
60333-710.102	ANTI-SARS-COV2 ANTIBODIES DERIVED FROM CR3022	US	63/074,083	03-Sep-2020	
60333-710.201	ANTI-SARS-COV-2 ANTIBODIES DERIVED FROM CR3022	US	15/931,649	14-May-2020	
60333-711.101	SUPERHUMAN ANTI- SARS-COV-2 ANTIBODIES AND USES THEREOF	US	63/013,485	21-Apr-2020	
60333-711.102	SUPERHUMAN ANTI- SARS-COV-2 ANTIBODIES AND	US	63/014,948	24-Apr-2020	

	USES THEREOF				
60333-711.103	SUPERHUMAN ANTI-SARS-COV-2 ANTIBODIES AND USES THEREOF	US	63/074,087	03-Sep-2020	
60333-711.201	SUPERHUMAN ANTI-SARS-COV-2 ANTIBODIES AND USES THEREOF	US	15/931,654	14-May-2020	